title: [Development of purified HFRS bivalent vaccine].
abstract: OBJECTIVE
  To develop the purified HFRS bivalent vaccine.
  
  
  METHODS
  LR1 (type I) and R22 (type II) of HFRS virus were cultured respectively in Vero cells. The viral suspensions were harvested, inactivated with beta-propiolactone, concentrated by ultra-filtration, purified by zone centrifugation, and desucrosed by column chromatography. The qualified vaccine bulks of type I and type II were mixed equally and absorbed with AI(OH)3 for preparation of 3 lots vaccines.
  
  
  RESULTS
  The 3 lots vaccines all passed examination carried out by ourselves and reexamination performed by National Institute for the Control of Pharmaceutical and Biological Products . One of 3 lots has been used in clinical trial.
  
  
  CONCLUSIONS
  It is practical to develop the purified HFRS bivalent vaccine by Vero cell culture.
authors.affiliation: Lanzhou Institute of Biological Products, Lanzhou 730046, China. yangsl186@sohu.com
authors.forename: Shi-long
authors.initials: SL
authors.lastname: Yang
authors.forename: Guan-mu
authors.initials: GM
authors.lastname: Dong
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Qi
authors.initials: Q
authors.lastname: An
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Sun
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Sun
authors.forename: Ping
authors.initials: P
authors.lastname: Li
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D002986:Clinical Trials as Topic; D018063:Hantaan virus / Q000276:immunology*; D006801:Humans; D007114:Immunization; D011786:Quality Control; D014709:Vero Cells; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D014765:Viral Vaccines